论文部分内容阅读
目的分析非小细胞肺癌(NSCLC)癌组织中ERCC1的表达状况及其与NSCLC的临床病理特征的关系。方法采用免疫组织化学法检测6 4例初治中晚期NSCLC患者癌组织中ERCC1基因的表达情况。结果 ERCC1表达的阳性率为4 3.8%,其表达与吸烟有密切关系,在吸烟组中的阳性率(27.8%)显著低于不吸烟组(6 4.3%)(x~2=8.5 3 0,P=0.0 0 4)。随着原发灶和疾病分期增加,ERCC1的阳性率有上升的趋势,但组间比较差异均无显著性(均为P>0.0 5)。ERCC1在腺癌和低分化癌组中的阳性率分别高于鳞癌和高、中分化组,但差异无显著性(P>0.0 5)。ERCC1的表达与年龄、性别和淋巴结转移状况等均未见显著性关联(均为P>0.0 5)。结论 ERCC1表达与NSCLC的一些临床病理学特征密切相关。
Objective To analyze the expression of ERCC1 in non-small cell lung cancer (NSCLC) and its relationship with the clinicopathological features of NSCLC. Methods Immunohistochemistry was used to detect the expression of ERCC1 gene in 64 cases of newly diagnosed and advanced NSCLC patients. Results The positive rate of ERCC1 expression was 43.8%. The expression of ERCC1 was closely related to smoking. The positive rate of ERCC1 in smoking group was significantly lower than that in non-smoking group (27.8% vs 62.3%, x ~ 2 = 8.530, P = 0.0 0 4). The positive rate of ERCC1 increased with the increase of primary tumor and stage of disease, but there was no significant difference between the two groups (all P> 0.0 5). The positive rate of ERCC1 in adenocarcinoma and poorly differentiated carcinoma was higher than that in squamous cell carcinoma and in moderate and high differentiated carcinoma, but the difference was not significant (P> 0.0 5). There was no significant correlation between ERCC1 expression and age, gender and lymph node metastasis (all P> 0.0 5). Conclusion The expression of ERCC1 is closely related to some clinicopathological features of NSCLC.